Clinical Studies
-
Evaluating the Tolerability of Combination of Verdinexor and Doxorubicin in Dogs with Cancer
Currently EnrollingVerdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.
Study Details -
Trial Evaluating an Investigational Agent for Management of Transitional Cell Carcinoma
ClosedThis trial is designed to evaluate the safety and preliminary pain management and anti-cancer effectiveness of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).
Study Details